Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FENNEC PHARMACEUTICALS INC.

(FENC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

FENNEC PHARMACEUTICALS INC. : Submission of Matters to a Vote of Security Holders (form 8-K)

06/30/2021 | 04:52pm EDT

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 29, 2021, Fennec Pharmaceuticals Inc. (the "Company") held an annual meeting of shareholders (the "Meeting"). The shareholders approved all proposals considered at the Meeting and approved all nominees of the Company for director, as follows:

1. The following six (6) nominees were elected to serve as directors, each to

    serve until the next annual meeting of shareholders of the Company or until
    their respective successor shall have been duly elected or duly approved:



Name of Nominee Votes For Votes Withheld Broker Non-Votes Dr. Khalid Islam 13,646,934 130,590 4,922,711 Adrian Haigh 13,419,749 357,775 4,922,711 Chris A. Rallis 13,611,818 165,706 4,922,711 Marco Brughera 13,517,839 259,685 4,922,711 Jodi Cook 13,519,400 258,124 4,922,711 Rostislav Raykov 13,656,957 120,567 4,922,711

2. The resolution to appoint Haskell & White LLP as independent public accounting

    firm of the Company and to authorize the Board of Directors to fix their
    remuneration was approved based on the following vote:




                           Votes For        18,675,716
                           Votes Withheld     21,855
                           Abstentions        2,758
                           Broker Non-Votes     0



3. The resolution to vote on the advisory vote on executive compensation was

approved based on the following vote:




                           Votes For        13,354,125
                           Votes Against     343,244
                           Abstentions       148,564
                           Broker Non-Votes 4,922,711






  2

© Edgar Online, source Glimpses

All news about FENNEC PHARMACEUTICALS INC.
09/09FENNEC PHARMACEUTICALS : to Participate in Upcoming Investor Conferences
AQ
08/10FENNEC PHARMACEUTICALS : Wedbush Lifts Price Target for Fennec Pharmaceuticals to $12 From..
MT
08/10FENNEC PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and R..
AQ
08/10FENNEC PHARMACEUTICALS : Reports Q2 Net loss of US$0.15 Per Share; Provides Business Updat..
MT
08/10FENNEC PHARMACEUTICALS : Earnings Flash (FRX.TO) FENNEC PHARMACEUTICALS Posts Net loss for..
MT
08/10FENNEC PHARMACEUTICALS : Earnings Flash (FRX.TO) FENNEC PHARMACEUTICALS Posts Net loss for..
MT
08/10Fennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Bus..
GL
08/06NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
06/30FENNEC PHARMACEUTICALS INC. : Submission of Matters to a Vote of Security Holders (form 8-..
AQ
06/29Fennec Announces Results of Annual Meeting
GL
More news
Analyst Recommendations on FENNEC PHARMACEUTICALS INC.
More recommendations
Financials (USD)
Sales 2021 21,0 M - -
Net income 2021 -17,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -13,2x
Yield 2021 -
Capitalization 228 M 228 M -
Capi. / Sales 2021 10,8x
Capi. / Sales 2022 11,3x
Nbr of Employees 9
Free-Float 83,1%
Chart FENNEC PHARMACEUTICALS INC.
Duration : Period :
Fennec Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FENNEC PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 8,76 $
Average target price 13,60 $
Spread / Average Target 55,3%
EPS Revisions
Managers and Directors
Rostislav C. Raykov Chief Executive Officer & Director
Robert C. Andrade Chief Financial Officer
Khalid Islam Chairman
Chris A. Rallis Independent Director
Adrian James Haigh Independent Director
Sector and Competitors
1st jan.Capi. (M$)
FENNEC PHARMACEUTICALS INC.17.58%228
GILEAD SCIENCES, INC.15.41%83 993
BIONTECH SE241.44%69 162
WUXI APPTEC CO., LTD.24.51%65 142
REGENERON PHARMACEUTICALS18.47%59 196
VERTEX PHARMACEUTICALS-22.35%48 536